Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Validation of the prognosis of patients with ER‑positive, HER2‑negative and node‑negative invasive breast cancer classified as low risk by Curebest™ 95GC Breast in a multi‑institutional registry study

Validation of the prognosis of patients with ER‑positive, HER2‑negative and node‑negative... Curebest™ 95GC breast (95GC) is a multigene classifier we developed for the prognostic prediction of patients with estrogen receptor (ER)‑positive, human epidermal growth factor receptor 2 (HER2)‑negative and node‑negative (ER+/HER2‑/n0) invasive breast cancer treated with adjuvant endocrine therapy alone. The aim of the preset study was to evaluate the clinical utility of 95GC in a multiinstitutional registry study. Patients (n=215) with ER+/HER2‑/n0 invasive breast cancer who had undergone the 95GC assay in seven hospitals were consecutively recruited in the registry study at various postoperative times. At recruitment, no patients had disease recurrences and were prospectively followed up for a median of 62 (range, 6‑91) postoperative months. Of the 124 patients classified as 95GC low risk, 118 received adjuvant endocrine therapy alone and six received adjuvant chemo‑endocrine therapy. Only two patients developed distant recurrences, and the 5‑year distant recurrence‑free survival (DRFS) was as high as 98.0%. Of the 91 patients classified as 95GC high risk, 81 received adjuvant chemo‑endocrine therapy and 10 received adjuvant endocrine therapy alone. A total of four of these patients developed distant recurrences (5‑year DRFS=95.5%). Among the 95GC high‑risk patients, prognosis was significantly improved for the 81 treated with adjuvant chemo‑endocrine therapy compared with for the 77 (historical controls) treated with adjuvant endocrine therapy alone (P=0.0002; hazard ratio, 0.24). Compared with the St. Gallen 2013 guideline, a significant de‑escalation from 73.1% (155/212) to 40.6% (86/212) in adjuvant chemotherapy was achieved. The excellent prognosis of patients with ER+/HER2‑/n0 invasive breast cancer classified as 95GC low risk could be validated in the present registry study, indicating that 95GC is useful for safe de‑escalation of adjuvant chemotherapy in patients with ER+/HER2‑/n0 invasive breast cancer. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology Letters Spandidos Publications

Validation of the prognosis of patients with ER‑positive, HER2‑negative and node‑negative invasive breast cancer classified as low risk by Curebest™ 95GC Breast in a multi‑institutional registry study

Download PDF
7 pages

Loading next page...
 
/lp/spandidos-publications/validation-of-the-prognosis-of-patients-with-er-positive-her2-negative-eXN6Z7hLW4
Publisher
Spandidos Publications
Copyright
Copyright \xC2\xA9 2023 Spandidos Publications
ISSN
1792-1074

Abstract

Curebest™ 95GC breast (95GC) is a multigene classifier we developed for the prognostic prediction of patients with estrogen receptor (ER)‑positive, human epidermal growth factor receptor 2 (HER2)‑negative and node‑negative (ER+/HER2‑/n0) invasive breast cancer treated with adjuvant endocrine therapy alone. The aim of the preset study was to evaluate the clinical utility of 95GC in a multiinstitutional registry study. Patients (n=215) with ER+/HER2‑/n0 invasive breast cancer who had undergone the 95GC assay in seven hospitals were consecutively recruited in the registry study at various postoperative times. At recruitment, no patients had disease recurrences and were prospectively followed up for a median of 62 (range, 6‑91) postoperative months. Of the 124 patients classified as 95GC low risk, 118 received adjuvant endocrine therapy alone and six received adjuvant chemo‑endocrine therapy. Only two patients developed distant recurrences, and the 5‑year distant recurrence‑free survival (DRFS) was as high as 98.0%. Of the 91 patients classified as 95GC high risk, 81 received adjuvant chemo‑endocrine therapy and 10 received adjuvant endocrine therapy alone. A total of four of these patients developed distant recurrences (5‑year DRFS=95.5%). Among the 95GC high‑risk patients, prognosis was significantly improved for the 81 treated with adjuvant chemo‑endocrine therapy compared with for the 77 (historical controls) treated with adjuvant endocrine therapy alone (P=0.0002; hazard ratio, 0.24). Compared with the St. Gallen 2013 guideline, a significant de‑escalation from 73.1% (155/212) to 40.6% (86/212) in adjuvant chemotherapy was achieved. The excellent prognosis of patients with ER+/HER2‑/n0 invasive breast cancer classified as 95GC low risk could be validated in the present registry study, indicating that 95GC is useful for safe de‑escalation of adjuvant chemotherapy in patients with ER+/HER2‑/n0 invasive breast cancer.

Journal

Oncology Letters – Spandidos Publications

Published: May 30, 2023

There are no references for this article.